A Phase 1 interventional study of ONO-7429 in Solid Tumors, sponsored by Ono Pharmaceutical Co., Ltd.. Recruiting at 10 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is to evaluate the tolerability and safety of ONO-7429 in participants with unresectable advanced or recurrent solid tumors.
Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ONO-7429
Specified dose on specified days
Dose-limiting toxicities(DLT)
Time frame: From first dose through completion of the DLT evaluation period (approximately 21 days)
Adverse event (AE)
Time frame: Approximately 6 months
Area under the Plasma Concentration versus Time Curve (AUC)
Time frame: Approximately 6 months
Cmax
Time frame: Approximately 6 months
Tmax
Time frame: Approximately 6 months
Terminal elimination half-life(T1/2)
Time frame: Approximately 6 months
Ctrough
Time frame: Approximately 6 months
CL
Time frame: Approximately 6 months
Volume of distribution at steady state(Vss)
Time frame: Approximately 6 months
Objective Response Rate (ORR)
Time frame: Approximately 6 months
Disease Control Rate (DCR)
Time frame: Approximately 6 months
Best overall response(BOR)
Time frame: Approximately 6 months
Duration of Response (DOR)
Time frame: Approximately 6 months
Progression-Free Survival (PFS)
Time frame: Approximately 6 months
Overall Survival (OS)
Time frame: Approximately 6 months
Time to Response (TTR)
Time frame: Approximately 6 months
Percent change from baseline in the sum of diameters of target lesions
Time frame: Approximately 6 months
Best percent change from baseline in the sum of diameters of target lesions
Time frame: Approximately 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Jul 2028, 25 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ono Pharmaceutical Co., Ltd. →